Harmony Biosciences Holdings (HRMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) has a cash flow conversion efficiency ratio of 0.093x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($92.43 Million) by net assets ($999.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HRMY market cap for the company's overall valuation and market capitalisation.
Harmony Biosciences Holdings - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Harmony Biosciences Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harmony Biosciences Holdings ranked by their cash flow conversion efficiency. Explore Harmony Biosciences Holdings cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tecnicas Reunidas
MC:TRE
|
0.027x |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
|
Legend Holdings Corporation
F:1PC
|
-0.009x |
|
Haemonetics Corporation
NYSE:HAE
|
0.089x |
|
Winner Medical Co Ltd
SHE:300888
|
0.031x |
|
Voltronic Power Technology Corp
TW:6409
|
0.046x |
|
Sixt SE
XETRA:SIX2
|
0.064x |
|
El Al Israel Airlines Ltd
TA:ELAL
|
0.127x |
Annual Cash Flow Conversion Efficiency for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Harmony Biosciences Holdings from 2018 to 2025. View latest Harmony Biosciences Holdings stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $870.22 Million | $348.20 Million | 0.400x | +19.98% |
| 2024-12-31 | $659.15 Million | $219.82 Million | 0.333x | -29.01% |
| 2023-12-31 | $466.99 Million | $219.39 Million | 0.470x | +31.00% |
| 2022-12-31 | $402.84 Million | $144.47 Million | 0.359x | -32.14% |
| 2021-12-31 | $186.51 Million | $98.56 Million | 0.528x | +1820.38% |
| 2020-12-31 | $97.18 Million | $-2.98 Million | -0.031x | -100.47% |
| 2019-12-31 | $-11.59 Million | $-75.44 Million | 6.512x | +1468.26% |
| 2018-12-31 | $81.53 Million | $-38.80 Million | -0.476x | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more